BC Cancer Agency Researchers Co-Lead $60 Million National Initiative for Innovative Cancer Treatments

VANCOUVER – BC Cancer Agency researchers will play a key role in the first Network of Centres of Excellence (NCE) devoted to cancer research, announced today with a $25 million commitment from the Government of Canada and an additional $35 million from partners across the country. The NCE, called BioCanRX, will focus on the development of new biotherapeutics – therapies derived from biological...

BC Cancer Agency lay the foundation for clinical trials involving "adoptive T cell therapy"

Dr. Brad Nelson, Director of the BC Cancer Agency’s Trev & Joyce Deeley Research Centre in Victoria, and his team lay the foundation for clinical trials involving a form of immunotherapy called “adoptive T cell therapy” or ACT. Groundbreaking cancer research has advanced from a concept to compelling scientific proof that enhancing the body’s natural immune response to cancer through ACT can...

BC Cancer Agency scientists make internationally significant discovery, mapping the evolution of breast cancer ‘avatars’

Vancouver – A just-published paper in the prestigious journal Nature highlights how researchers at the BC Cancer Agency are using human breast cancer ‘avatars’ — models of human breast cancers — to measure how complex cancers develop and change over time. The research is unprecedented because it uses single cancer cells to expose how breast cancers evolve and how to identify the cell populations...

Personalized Onco-Genomics sets a global precedent

The Personalized Onco-Genomics (POG) Program sets a global precedent both in terms of the diversity of cancers investigated and the number of patients participating. The 2014 Inspiration Gala raised $5 million to support part II of POG, seeing more than 300 patients enter a world-first clinical study that provides oncologists with gamechanging genomic data to guide treatment decisions. POG is a...

The BC Cancer Agency’s Genito-Urinary tumour group and Radiotherapy Program approve and implement HDR brachytherapy “boost”

The BC Cancer Agency’s Genito-Urinary tumour group and Radiotherapy Program approve and implement HDR brachytherapy “boost” (implanted radiation in addition to standard external beam radiation) as standard treatment for patients with both high-tier intermediate and high-risk prostate cancer, meaning this evolutionary treatment improvement will benefit patients who need it most. HDR brachytherapy...

Researchers conduct the Intra-Tumoural Heterogeneity Subproject

Fundraising support for childhood cancer research at the BC Cancer Agency enables researchers to conduct the Intra-Tumoural Heterogeneity Subproject, a study of important clinical significance to the overall MAGIC (Medulloblastoma Advanced Genomics International Consortium) project. The MAGIC project began with the genomic analysis of 1,000 pediatric medulloblastoma samples, representing the four...

Centre for Lymphoid Cancer is among the top lymphoid cancer research centres in the world

The Agency’s Centre for Lymphoid Cancer (CLC) is one of the top lymphoid cancer research centres in the world, based on the strength of its team of researchers, emphasis on a multi-disciplinary approach to new treatments and diagnostics and access to a comprehensive tumour tissue bank and outcomes unit database. Support has enabled researchers to build infrastructure for a provincial treatment...

First in Canada cancer biobank registers 10,000 participants

VANCOUVER, B.C. – The PREDICT (Personal Response Determinants in Cancer Therapy) program at the BC Cancer Agency has registered 10,000 participants. This number is significant because it is half way to the program’s goal of 20,000 participants – a number which will enable large scale cancer and genomic research. The program launched as a pilot project in 2006, thanks to the generosity of BC...

BC-developed prostate cancer drug holds out hope for clinical trials

VANCOUVER, B.C. – A new potential prostate cancer drug developed by the BC Cancer Agency offers hope where other drugs have failed. EPI-001 was developed by Dr. Marianne Sadar, distinguished scientist, BC Cancer Agency, and Dr. Raymond Andersen, distinguished professor, University of British Columbia. Research published today in the Journal of Clinical Investigation confirms that Dr. Sadar’s team...

First-in-Canada technology helps cancer specialists to better detect lung cancer

BC Cancer Foundation donors support major enhancement to lung cancer care
Vancouver – Lung cancer specialists at the BC Cancer Agency now have access to a three-dimensional navigation system that can enhance diagnosis, staging and care for lung cancer patients in BC. The BC Cancer Foundation-funded equipment is the first of its kind to be used in Canada and is newly-installed at the BC Cancer Agency’s Vancouver Centre. “This technology acts as a GPS, providing clear...

Pages